Biomarin Pharmaceutical Inc (BMRN) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Earnings Press Release
10-Q Quarterly Report
10-Q QoQ Changes
Biomarin Pharmaceutical Inc
Ticker: BMRN CIK: 1048477

Exhibit 99.1

Contact:
Investors:		Media:
Traci McCarty		Debra Charlesworth
BioMarin Pharmaceutical Inc.		BioMarin Pharmaceutical Inc.
(415) 455-7558		(415) 455-7451

BioMarin Announces Third Quarter 2018 Results

- First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion

- 124 Commercial Patients Receiving Treatment with Palynziq in First Full Quarter since U.S. Approval

- Vosoritide 42-Month Data; PKU Gene Therapy Preclinical Data and Research Deep Dive

at R&D Day on November 7 in New York City

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)

	Three Months Ended September 30,									Nine Months Ended September 30,
	2018			2017			% Change			2018			2017			% Change

Total Revenues	$	391.7		$	334.1			17	%	$	1,138.0		$	955.3			19	%
Vimizim Net Product Revenues		123.3			90.3			37	%		368.0			299.3			23	%
Kuvan Net Product Revenues		113.3			105.8			7	%		321.4			300.1			7	%
Naglazyme Net Product Revenues		103.1			72.1			43	%		269.2			238.4			13	%
Aldurazyme Net Product Revenues		27.6			22.4			23	%		117.7			61.7			91	%
Brineura Net Product Revenues		9.9			3.1			219	%		27.7			3.4			715	%
Palynziq Net Product Revenues		4.1			—		n/a				4.1			—		n/a

GAAP Net Loss	$	(12.6	)	$	(12.5	)				$	(73.6	)	$	(65.7	)
GAAP Net Loss per Share - Basic and Diluted	$	(0.07	)	$	(0.07	)				$	(0.42	)	$	(0.38	)

Non-GAAP Income ⁽¹⁾	$	60.7		$	7.8					$	101.8		$	68.7

	September 30,			December 31,
	2018			2017
Cash, cash equivalents and investments	$	1,648.3		$	1,781.7

(1)

Non-GAAP Income is defined by the Company as reported GAAP Net Income (Loss), excluding net interest expense, provision for (benefit from) income taxes, depreciation expense, amortization expense, stock-based compensation expense, contingent consideration expense and, in certain periods, certain other specified items. Refer to Non-GAAP Information beginning on page 9 of this press release for a complete discussion of the Company’s Non-GAAP financial information and reconciliations to the comparable information reported under Generally Accepted Accounting Principles in the United States (US GAAP).

The following information was filed by Biomarin Pharmaceutical Inc (BMRN) on Thursday, October 25, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Biomarin Pharmaceutical Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Biomarin Pharmaceutical Inc.

Continue

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1048477/000156459018025196/bmrn-10q_20180930.htm